Form 4: ImmunityBio Director Sells 75,000 Shares

ImmunityBio Director Barry J. Simon sold 75,000 shares of common stock for approximately $12.01 per share under a pre-arranged trading plan.

Summary

• Barry J. Simon, a Director and 10% Owner of ImmunityBio, Inc. (IBRX), disposed of 75,000 shares of common stock.
• The transaction occurred on February 24, 2026, at a weighted average price of $12.0105 per share.
• The total value of the shares sold was approximately $900,787.50.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Simon on September 4, 2024.
• Following this transaction, Mr. Simon beneficially owns 2,850,821 shares of ImmunityBio common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal, as a director's sale of shares, even pre-planned, can raise questions about future prospects or personal liquidity needs, potentially impacting investor confidence.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance and not necessarily based on new, material non-public information.

Negatives

• A director's sale of a significant number of shares can be perceived negatively by the market, potentially signaling a lack of confidence or a need for personal liquidity.

Risks

• Investor sentiment could be negatively impacted by a director's share sale, potentially leading to downward pressure on the stock price.
• While executed under a 10b5-1 plan, the sale still represents a reduction in insider ownership, which some investors may interpret as a risk.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales, even when executed under Rule 10b5-1 plans, are closely monitored by investors as they can sometimes influence market perception regarding a company's near-term prospects or valuation. While pre-planned, such sales are still a reduction in insider exposure.

Stakeholder Impact

• Shareholders may view the director's sale with caution, potentially leading to a re-evaluation of their investment thesis or a short-term negative impact on share price.

Key Dates

Recommendation

While a director's sale of shares can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 trading plan, suggesting it was not based on new, material non-public information. Investors should monitor future insider activity and company performance rather than reacting solely to this single event, maintaining a 'hold' position pending further developments.

Keywords

ImmunityBio, IBRX, Form 4, insider trading, director sale, stock sale, 10b5-1 plan, beneficial ownership